


This listing of claims will replace all prior versions, and listings, of claims in the application:

**Listing of Claims:**

1. (Currently Amended) A compound of formula I  
in which



- X denotes CH or N,  
 $R^1$  denotes H, A, Hal,  $(CH_2)_n$ Het,  $(CH_2)_n$ Ar, cycloalkyl having 3 to 7 C atoms,  $CF_3$ ,  $NO_2$ , CN,  $C(NH)NOH$  or  $OCF_3$ ,  
 $R^2$  denotes  $(CH_2)_n$ Het,  $(CH_2)_n$ Ar, cycloalkyl having 3 to 7 C atoms or  $CF_3$ ,  
 $R^3, R^4$  denote H,  $(CH_2)_nCO_2R^5$ ,  $(CH_2)_nCOHet$ ,  $(CH_2)_nCON(R^5)_2$ ,  
 $(CH_2)_nCOO(CH_2)_nHet$ ,  $CHO$ ,  $(CH_2)_nOR^5$ ,  $(CH_2)_nHet$ ,  $(CH_2)_nN(R^5)_2$ ,  
 $CH=N-OA$ ,  $CH_2CH=N-OA$ ,  $(CH_2)_nNHOA$ ,  $(CH_2)_nN(R^5)Het$ ,  
 $(CH_2)_nCH=N-Het$ ,  $(CH_2)_nOCOR^5$ ,  $(CH_2)_nN(R^5)CH_2CH_2OR^5$ ,  
 $(CH_2)_nN(R^5)CH_2CH_2OCF_3$ ,  $(CH_2)_nN(R^5)C(R^5)HCOOR^5$ ,  
 $(CH_2)_nN(R^5)CH_2COHet$ ,  $(CH_2)_nN(R^5)CH_2Het$ ,  
 $(CH_2)_nN(R^5)CH_2CH_2Het$ ,  $(CH_2)_nN(R^5)CH_2CH_2N(R^5)CH_2COOR^5$ ,  
 $(CH_2)_nN(R^5)CH_2CH_2OR^5$ ,  $(CH_2)_nN(R^5)CH_2CH_2N(R^5)_2$ ,  
 $CH=CHCOOR^5$ ,  $CH=CHCH_2NR^5Het$ ,  $CH=CHCH_2N(R^5)_2$ ,  
 $CH=CHCH_2OR^5$ ,  $CH=CHCH_2Het$ ,  $(CH_2)_nN(R^5)Ar$ ,  
 $(CH_2)_nN(COOR^5)COOR^5$ ,  $(CH_2)_nN(CONH_2)COOR^5$ ,  
 $(CH_2)_nN(CONH_2)CONH_2$ ,  $(CH_2)_nN(CH_2COOR^5)COOR^5$ ,  
 $(CH_2)_nN(CH_2CONH_2)COOR^5$ ,  $(CH_2)_nN(CH_2CONH_2)CONH_2$ ,  
 $(CH_2)_nCHR^5COR^5$ ,  $(CH_2)_nCHR^5COOR^5$ , or  $(CH_2)_nCHR^5CH_2OR^5$ ,  
where in each case only one of the radicals  $R^3$  or  $R^4$  has can have  
the meaning H,  
 $R^5$  denotes H or A  
A denotes straight-chain or branched alkyl having 1 to 10 C atoms,

alkenyl having 2 to 10 C atoms, alkoxyalkyl having 2 to 10 C atoms or cycloalkyl having 4 to 7 C atoms, each of which is unsubstituted or substituted by Hal or CN,

Het denotes a saturated, unsaturated or aromatic mono- or bicyclic heterocyclic radical having 1 to 15 C atoms which is unsubstituted or mono- or polysubstituted by A and/or Hal or a linear radical having 1 to 15 C atoms containing one or two hetero atoms,

Ar denotes a phenyl radical which is unsubstituted or mono- or polysubstituted by A and/or Hal, OR<sup>5</sup>, OCOR<sup>5</sup>, COOR<sup>5</sup>, CON(R<sup>5</sup>)<sub>2</sub>, CN, NO<sub>2</sub>, NH<sub>2</sub>, NHCOR<sup>5</sup>, CF<sub>3</sub> or SO<sub>2</sub>CH<sub>3</sub>,

n denotes 0, 1, 2, 3, 4 or 5, and

Hal denotes F, Cl, Br or I,

or a salt, solvate, enantiomer or racemate thereof.

2. (Previously Presented) A compound according to claim 1, wherein the compound of formula I has a 5-HT receptor-antagonistic action.

3. (Previously Presented) A compound according to claim 1, wherein the compound of formula I has a 5-HT<sub>2A</sub> receptor-antagonistic action.

4. (Withdrawn) A method according to claim 21, wherein the disease is psychoses, a neurological disorder, amyotrophic lateral sclerosis, an eating disorder, bulimia, anorexia nervosa, premenstrual syndrome or obsessive-compulsive disorder (OCD).

5. (Withdrawn) A compound according to claim 1, in which R<sup>1</sup> denotes phenyl, 2-, 3- or 4-cyanophenyl, 2-, 3- or 4-fluorophenyl, 2-, 3- or 4-methyl-, ethyl-, n-propyl- or n-butylphenyl, 2,3-, 2,4-, 2,5-, 2,6-, 3,4-, 3,5- or 3,6-difluoro-, dichloro- or dicyanophenyl, 3,4,5-trifluorophenyl, 3,4,5-trimethoxy- or triethoxyphenyl, thiophen-2-yl or thiophen-3-yl or 1-, 2- or 3-pyrrolyl.

6. (Withdrawn) A compound according to claim 1, in which R<sup>3</sup> denotes (CH<sub>2</sub>)<sub>n</sub>CO<sub>2</sub>R<sup>5</sup>, (CH<sub>2</sub>)<sub>n</sub>CO-Het, CHO, CH<sub>2</sub>OR<sup>5</sup>, (CH<sub>2</sub>)<sub>n</sub>-Het, (CH<sub>2</sub>)<sub>n</sub>N(R<sup>5</sup>)<sub>2</sub>, CH=N-OA,

$(\text{CH}_2)_n\text{N}(\text{R}^5)\text{Het}$ ,  $(\text{CH}_2)_n\text{N}(\text{R}^5)\text{CH}_2\text{CH}_2\text{OR}^5$ ,  $(\text{CH}_2)_n\text{N}(\text{R}^5)\text{CH}_2\text{Het}$ ,  
 $(\text{CH}_2)_n\text{N}(\text{R}^5)\text{CH}_2\text{CH}_2\text{Het}$ ,  $(\text{CH}_2)_n\text{N}(\text{R}^5)\text{CH}_2\text{CH}_2\text{N}(\text{R}^5)_2$ ,  $\text{CH}=\text{CHCH}_2\text{NR}^5\text{Het}$ ,  
 $\text{CH}=\text{CHCH}_2\text{N}(\text{R}^5)_2$ ,  $\text{CH}=\text{CHCH}_2\text{OR}^5$ ,  $\text{CH}=\text{CHCH}_2\text{Het}$  or  $(\text{CH}_2)_n\text{N}(\text{R}^5)\text{Ar}$ .

7. (Previously Presented) A compound according to claim 1, in which  $\text{R}^4$  denotes H.

8. (Previously Presented) A compound according to claim 1, in which  $\text{R}^2$  denotes phenyl, 2-, 3- or 4-cyanophenyl, 2-, 3- or 4-fluorophenyl, 2-, 3- or 4-methyl-, ethyl-, n-propyl- or n-butylphenyl, 2,3-, 2,4-, 2,5-, 2,6-difluoro- or dicyanophenyl, thiophen-2-yl or thiophen-3-yl, 2-, 3- or 4-pyridyl, 2-, 4- or 5-oxazolyl, 2-, 4- or 5-thiazolyl, quinoliny, isoquinoliny, 2- or 4-pyridazyl, 2-, 4- or 5-pyrimidyl, 2- or 3-pyrazinyl, 2- or 3-furyl.

9. (Previously Presented) A compound according to claim 1, in which X has the meaning CH.


10. (Cancelled)

11. (Withdrawn) A compound according to claim 1, wherein the compound of formula I is  
 [1-biphenyl-4-yl-5-(2-fluorophenyl)-1 H-pyrazol-4-ylmethyl]-(4-methylpiperazin-1-yl)amine;  
 4-{2-[1-biphenyl-4-yl-5-(2-fluorophenyl)-1 H-pyrazol-4-yl]-ethyl}morpholine;  
 4-{3-[1-biphenyl-4-yl-5-(2-fluorophenyl)-1 H-pyrazol-4-yl]allyl}morpholine;  
 1-[1-biphenyl-4-yl-5-(2-fluorophenyl)-1 H-pyrazol-4-yl-methyl]pyrrolidin-3-ol;  
 1-[1-(4'-fluorobiphenyl-4-yl)-5-(2-fluorophenyl)-1 H-pyrazol-4-ylmethyl]-4-methylpiperazine;  
 1-[5-(2-fluorophenyl)-1-(4-thiophen-3-ylphenyl)-1 H-pyrazol-4-ylmethyl]-4-methylpiperazine;  
 1-[5-furan-2-yl-1-(4-thiophen-3-ylphenyl)-1 H-pyrazol-4-yl-methyl]-4-methylpiperazine;  
 N1-[1-biphenyl-4-yl-5-(2-fluorophenyl)-1 H-pyrazol-4-yl-methyl]ethane-1,2-diamine;

2-[[1-biphenyl-4-yl-5-(2-fluorophenyl)-1 H-pyrazol-4-yl-methyl]amino}ethanol;  
 [1 -biphenyl-4-yl-5-(2-fluorophenyl)-1 H-pyrazol-4-ylmethyl]-(2-methoxyethyl)amine;  
 2-[[1-biphenyl-4-yl-5-(2-fluorophenyl)-1 H-pyrazol-4-yl-methyl]methylamino}ethanol;  
 1-[1-biphenyl-4-yl-5-(2-fluorophenyl)-1 H-pyrazol-4-yl-methyl]-4-methyl-  
 [1,4]diazepam;  
 1-[1-(4'-fluorobiphenyl-4-yl)-5-phenyl-1 H-pyrazol-4-yl-methyl]-4-methylpiperazine;  
 1-[5-(2-fluorophenyl)-1-(4-pyrrol-1-ylphenyl)-1 H-pyrazol-4-ylmethyl]-4-  
 methylpiperazine; or  
 [1-biphenyl-4-yl-5-(2-fluorophenyl)-1 H-pyrazol-4-ylmethyl]-methyl-(1 -  
 methylpyrrolidin-3-yl)amine;  
 or a salt or solvate thereof.

12. (Withdrawn) A method according to claim 21, which is for the treatment of psychoses, a neurological disorder, amyotrophic lateral sclerosis, an eating disorder, bulimia, anorexia nervosa, premenstrual syndrome or obsessive-compulsive disorder (OCD).

13. (Currently Amended) A compound of formula I  
 in which



- X denotes CH or N,  
 R<sup>1</sup> denotes H, A, Hal, (CH<sub>2</sub>)<sub>n</sub>Het, (CH<sub>2</sub>)<sub>n</sub>Ar, cycloalkyl having 3 to 7 C atoms, CF<sub>3</sub>, NO<sub>2</sub>, CN, C(NH)NOH or OCF<sub>3</sub>,  
 R<sup>2</sup> denotes (CH<sub>2</sub>)<sub>n</sub>Het, (CH<sub>2</sub>)<sub>n</sub>Ar, cycloalkyl having 3 to 7 C atoms or CF<sub>3</sub>,  
 R<sup>3</sup>, R<sup>4</sup> denote H, (CH<sub>2</sub>)<sub>n</sub>CO<sub>2</sub>R<sup>5</sup>, (CH<sub>2</sub>)<sub>n</sub>COHet, (CH<sub>2</sub>)<sub>n</sub>CON(R<sup>5</sup>)<sub>2</sub>,  
 (CH<sub>2</sub>)<sub>n</sub>COO(CH<sub>2</sub>)<sub>n</sub>Het, CHO, (CH<sub>2</sub>)<sub>n</sub>OR<sup>5</sup>, (CH<sub>2</sub>)<sub>n</sub>Het, (CH<sub>2</sub>)<sub>n</sub>N(R<sup>5</sup>)<sub>2</sub>,  
 CH=N-OA, CH<sub>2</sub>CH=N-OA, (CH<sub>2</sub>)<sub>n</sub>NHOA, (CH<sub>2</sub>)<sub>n</sub>N(R<sup>5</sup>)Het,  
 (CH<sub>2</sub>)<sub>n</sub>CH=N-Het, (CH<sub>2</sub>)<sub>n</sub>OCOR<sup>5</sup>, (CH<sub>2</sub>)<sub>n</sub>N(R<sup>5</sup>)CH<sub>2</sub>CH<sub>2</sub>OR<sup>5</sup>,  
 (CH<sub>2</sub>)<sub>n</sub>N(R<sup>5</sup>)CH<sub>2</sub>CH<sub>2</sub>OCF<sub>3</sub>, (CH<sub>2</sub>)<sub>n</sub>N(R<sup>5</sup>)C(R<sup>5</sup>)HCOOR<sup>5</sup>,

$(\text{CH}_2)_n\text{N}(\text{R}^5)\text{CH}_2\text{COHet}$ ,  $(\text{CH}_2)_n\text{N}(\text{R}^5)\text{CH}_2\text{Het}$ ,  
 $(\text{CH}_2)_n\text{N}(\text{R}^5)\text{CH}_2\text{CH}_2\text{Het}$ ,  $(\text{CH}_2)_n\text{N}(\text{R}^5)\text{CH}_2\text{CH}_2\text{N}(\text{R}^5)\text{CH}_2\text{COOR}^5$ ,  
 $(\text{CH}_2)_n\text{N}(\text{R}^5)\text{CH}_2\text{CH}_2\text{OR}^5$ ,  $(\text{CH}_2)_n\text{N}(\text{R}^5)\text{CH}_2\text{CH}_2\text{N}(\text{R}^5)_2$ ,  
 $\text{CH}=\text{CHCOOR}^5$ ,  $\text{CH}=\text{CHCH}_2\text{NR}^5\text{Het}$ ,  $\text{CH}=\text{CHCH}_2\text{N}(\text{R}^5)_2$ ,  
 $\text{CH}=\text{CHCH}_2\text{OR}^5$ ,  $\text{CH}=\text{CHCH}_2\text{Het}$ ,  $(\text{CH}_2)_n\text{N}(\text{R}^5)\text{Ar}$ ,  
 $(\text{CH}_2)_n\text{N}(\text{COOR}^5)\text{COOR}^5$ ,  $(\text{CH}_2)_n\text{N}(\text{CONH}_2)\text{COOR}^5$ ,  
 $(\text{CH}_2)_n\text{N}(\text{CONH}_2)\text{CONH}_2$ ,  $(\text{CH}_2)_n\text{N}(\text{CH}_2\text{COOR}^5)\text{COOR}^5$ ,  
 $(\text{CH}_2)_n\text{N}(\text{CH}_2\text{CONH}_2)\text{COOR}^5$ ,  $(\text{CH}_2)_n\text{N}(\text{CH}_2\text{CONH}_2)\text{CONH}_2$ ,  
 $(\text{CH}_2)_n\text{CHR}^5\text{COR}^5$ ,  $(\text{CH}_2)_n\text{CHR}^5\text{COOR}^5$ , or  $(\text{CH}_2)_n\text{CHR}^5\text{CH}_2\text{OR}^5$ ,  
 where in each case only one of the radicals  $\text{R}^3$  or  $\text{R}^4$  has can have  
 the meaning H,

$\text{R}^5$  denotes H or A

A denotes straight-chain or branched alkyl having 1 to 10 C atoms, alkenyl having 2 to 10 C atoms, alkoxyalkyl having 2 to 10 C atoms or cycloalkyl having 4 to 7 C atoms, each of which is unsubstituted or substituted by Hal or CN,

Het denotes a saturated, unsaturated or aromatic mono- or bicyclic heterocyclic radical having 1 to 15 C atoms which is unsubstituted or mono- or polysubstituted by A and/or Hal or a linear radical having 1 to 15 C atoms containing one or two hetero atoms,

Ar denotes a phenyl radical which is unsubstituted or mono- or polysubstituted by A and/or Hal,  $\text{OR}^5$ ,  $\text{OCOR}^5$ ,  $\text{COOR}^5$ ,  $\text{CON}(\text{R}^5)_2$ , CN,  $\text{NO}_2$ ,  $\text{NH}_2$ ,  $\text{NHCOR}^5$ ,  $\text{CF}_3$  or  $\text{SO}_2\text{CH}_3$ ,

n denotes 0, 1, 2, 3, 4 or 5, and

Hal denotes F, Cl, Br or I,

or a salt thereof.

14. (Withdrawn) A compound according to claim 13, wherein the compound of formula I is
- [1-biphenyl-4-yl-5-(2-fluorophenyl)-1 H-pyrazol-4-ylmethyl]-(4-methylpiperazin-1-yl)amine;
- 4-{2-[1-biphenyl-4-yl-5-(2-fluorophenyl)-1 H-pyrazol-4-yl]-ethyl}morpholine;
- 4-{3-[1-biphenyl-4-yl-5-(2-fluorophenyl)-1 H-pyrazol-4-yl]allyl}morpholine;

1-[1-biphenyl-4-yl-5-(2-fluorophenyl)-1 H-pyrazol-4-yl-methyl]pyrrolidin-3-ol;  
 1-[1-(4'-fluorobiphenyl-4-yl)-5-(2-fluorophenyl)-1 H-pyrazol-4-ylmethyl]-4-methylpiperazine;  
 1-[5-(2-fluorophenyl)-1-(4-thiophen-3-ylphenyl)-1 H-pyrazol-4-ylmethyl]-4-methylpiperazine;  
 1-[5-furan-2-yl-1-(4-thiophen-3-ylphenyl)-1 H-pyrazol-4-yl-methyl]-4-methylpiperazine;  
 N1-[1-biphenyl-4-yl-5-(2-fluorophenyl)-1 H-pyrazol-4-yl-methyl]ethane-1,2-diamine;  
 2-[[1-biphenyl-4-yl-5-(2-fluorophenyl)-1 H-pyrazol-4-yl-methyl]amino}ethanol;  
 [1 -biphenyl-4-yl-5-(2-fluorophenyl)-1 H-pyrazol-4-ylmethyl]-(2-methoxyethyl)amine;  
 2-[[1-biphenyl-4-yl-5-(2-fluorophenyl)-1 H-pyrazol-4-yl-methyl]methylamino}ethanol;  
 1-[1-biphenyl-4-yl-5-(2-fluorophenyl)-1 H-pyrazol-4-yl-methyl]-4-methyl-[1,4]diazepam;  
 1-[1-(4'-fluorobiphenyl-4-yl)-5-phenyl-1 H-pyrazol-4-yl-methyl]-4-methylpiperazine;  
 1-[5-(2-fluorophenyl)-1-(4-pyrrol-1-ylphenyl)-1 H-pyrazol-4-ylmethyl]-4-methylpiperazine; or  
 [1-biphenyl-4-yl-5-(2-fluorophenyl)-1 H-pyrazol-4-ylmethyl]-methyl-(1 -methylpyrrolidin-3-yl)amine;  
 or a salt thereof.

15. (Withdrawn) A method for the treatment of psychoses, a neurological disorder, amyotrophic lateral sclerosis, an eating disorder, bulimia, anorexia nervosa, premenstrual syndrome or obsessive-compulsive disorder (OCD), comprising administering to a subject in need thereof an effective amount of a compound according to claim 13.

16. (Withdrawn) A method for the treatment of psychoses, a neurological disorder, amyotrophic lateral sclerosis, an eating disorder, bulimia, anorexia nervosa, premenstrual syndrome or obsessive-compulsive disorder (OCD), comprising administering to a subject in need thereof an effective amount of a compound according to claim 14.

17. (Withdrawn) A compound according to claim 1, in which R<sup>1</sup> denotes phenyl, 2-, 3- or 4-cyanophenyl, 2-, 3- or 4-fluorophenyl, 2-, 3- or 4-

methyl-, ethyl-, n-propyl- or n-butylphenyl, 2,3-, 2,4-, 2,5-, 2,6-, 3,4-, 3,5- or 3,6-difluoro-, dichloro- or dicyanophenyl, 3,4,5-trifluorophenyl, 3,4,5-trimethoxy- or triethoxyphenyl, thiophen-2-yl or thiophen-3-yl or 1-, 2- or 3-pyrrolyl,

$R^3$  denotes  $(CH_2)_nCO_2R^5$ ,  $(CH_2)_nCO-Het$ ,  $CHO$ ,  $CH_2OR^5$ ,  $(CH_2)_n-Het$ ,  $(CH_2)_nN(R^5)_2$ ,  $CH=N-OA$ ,  $(CH_2)_nN(R^5)Het$ ,  $(CH_2)_nN(R^5)CH_2CH_2OR^5$ ,  $(CH_2)_nN(R^5)CH_2Het$ ,  $(CH_2)_nN(R^5)CH_2CH_2Het$ ,  $(CH_2)_nN(R^5)CH_2CH_2N(R^5)_2$ ,  $CH=CHCH_2NR^5Het$ ,  $CH=CHCH_2N(R^5)_2$ ,  $CH=CHCH_2OR^5$ ,  $CH=CHCH_2Het$  or  $(CH_2)_nN(R^5)Ar$ ,

$R^4$  denotes H,

$R^2$  denotes phenyl, 2-, 3- or 4-cyanophenyl, 2-, 3- or 4-fluorophenyl, 2-, 3- or 4-methyl-, ethyl-, n-propyl- or n-butylphenyl, 2,3-, 2,4-, 2,5-, 2,6-difluoro- or dicyanophenyl, thiophen-2-yl or thiophen-3-yl, 2-, 3- or 4-pyridyl, 2-, 4- or 5-oxazolyl, 2-, 4- or 5-thiazolyl, quinolinyl, isoquinolinyl, 2- or 4-pyridazyl, 2-, 4- or 5-pyrimidyl, 2- or 3-pyrazinyl, 2- or 3-furyl, and

X has the meaning CH.

18. (Withdrawn) A compound according to claim 13, in which

$R^1$  denotes phenyl, 2-, 3- or 4-cyanophenyl, 2-, 3- or 4-fluorophenyl, 2-, 3- or 4-methyl-, ethyl-, n-propyl- or n-butylphenyl, 2,3-, 2,4-, 2,5-, 2,6-, 3,4-, 3,5- or 3,6-difluoro-, dichloro- or dicyanophenyl, 3,4,5-trifluorophenyl, 3,4,5-trimethoxy- or triethoxyphenyl, thiophen-2-yl or thiophen-3-yl or 1-, 2- or 3-pyrrolyl,

$R^3$  denotes  $(CH_2)_nCO_2R^5$ ,  $(CH_2)_nCO-Het$ ,  $CHO$ ,  $CH_2OR^5$ ,  $(CH_2)_n-Het$ ,  $(CH_2)_nN(R^5)_2$ ,  $CH=N-OA$ ,  $(CH_2)_nN(R^5)Het$ ,  $(CH_2)_nN(R^5)CH_2CH_2OR^5$ ,  $(CH_2)_nN(R^5)CH_2Het$ ,  $(CH_2)_nN(R^5)CH_2CH_2Het$ ,  $(CH_2)_nN(R^5)CH_2CH_2N(R^5)_2$ ,  $CH=CHCH_2NR^5Het$ ,  $CH=CHCH_2N(R^5)_2$ ,  $CH=CHCH_2OR^5$ ,  $CH=CHCH_2Het$  or  $(CH_2)_nN(R^5)Ar$ ,

$R^4$  denotes H,

$R^2$  denotes phenyl, 2-, 3- or 4-cyanophenyl, 2-, 3- or 4-fluorophenyl, 2-, 3- or 4-methyl-, ethyl-, n-propyl- or n-butylphenyl, 2,3-, 2,4-, 2,5-, 2,6-difluoro- or dicyanophenyl, thiophen-2-yl or thiophen-3-yl, 2-, 3- or 4-pyridyl, 2-, 4- or 5-oxazolyl, 2-, 4- or 5-thiazolyl, quinolinyl, isoquinolinyl, 2- or 4-pyridazyl, 2-, 4- or 5-pyrimidyl, 2- or 3-pyrazinyl, 2- or 3-furyl, and

X has the meaning CH.

19. (Withdrawn) A method for the treatment of psychoses, a neurological disorder, amyotrophic lateral sclerosis, an eating disorder, bulimia, anorexia nervosa, premenstrual syndrome or obsessive-compulsive disorder (OCD), comprising administering to a subject in need thereof an effective amount of a compound according to claim 17.

20. (Withdrawn) A method for the treatment of psychoses, a neurological disorder, amyotrophic lateral sclerosis, an eating disorder, bulimia, anorexia nervosa, premenstrual syndrome or obsessive-compulsive disorder (OCD), comprising administering to a subject in need thereof an effective amount of a compound according to claim 18.

21. (Withdrawn) A method for the treatment or prophylaxis of a disease which can be influenced by the binding of a compound formula I to a 5 HT receptor, comprising administering to a subject in need thereof an effective amount of a compound according to claim 1.